Nuvectra (NVTR) Trading Down 5.4%

Nuvectra Corp (NASDAQ:NVTR) shares traded down 5.4% during mid-day trading on Wednesday . The stock traded as low as $5.05 and last traded at $5.09. 506,936 shares were traded during trading, an increase of 110% from the average session volume of 241,960 shares. The stock had previously closed at $5.38.

Several research analysts have issued reports on the stock. BidaskClub upgraded shares of Nuvectra from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. ValuEngine cut shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. Raymond James dropped their target price on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, JMP Securities dropped their target price on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Nuvectra has a consensus rating of “Hold” and a consensus price target of $20.40.

The firm has a market cap of $93.81 million, a price-to-earnings ratio of -1.60 and a beta of -0.19. The company has a current ratio of 6.60, a quick ratio of 6.07 and a debt-to-equity ratio of 0.56.

Nuvectra (NASDAQ:NVTR) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.18). Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%. The firm had revenue of $11.13 million during the quarter, compared to the consensus estimate of $12.76 million. Equities analysts forecast that Nuvectra Corp will post -3.03 EPS for the current year.

In other news, Director David D. Johnson purchased 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were acquired at an average cost of $6.12 per share, for a total transaction of $122,400.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 2.90% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Nuvectra by 27.9% in the 4th quarter. BlackRock Inc. now owns 1,223,250 shares of the company’s stock valued at $19,989,000 after purchasing an additional 267,052 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Nuvectra by 11.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 764,043 shares of the company’s stock valued at $8,412,000 after purchasing an additional 77,413 shares during the last quarter. Cannell Capital LLC raised its position in shares of Nuvectra by 2,750.6% in the 1st quarter. Cannell Capital LLC now owns 723,349 shares of the company’s stock valued at $7,964,000 after purchasing an additional 697,974 shares during the last quarter. Vanguard Group Inc raised its position in shares of Nuvectra by 13.1% in the 3rd quarter. Vanguard Group Inc now owns 677,798 shares of the company’s stock valued at $14,898,000 after purchasing an additional 78,724 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Nuvectra by 13.1% in the 3rd quarter. Vanguard Group Inc. now owns 677,798 shares of the company’s stock valued at $14,898,000 after purchasing an additional 78,724 shares during the last quarter. Institutional investors and hedge funds own 82.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Nuvectra (NVTR) Trading Down 5.4%” was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.themarketsdaily.com/2019/05/16/nuvectra-nvtr-trading-down-5-4.html.

Nuvectra Company Profile (NASDAQ:NVTR)

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Featured Article: What is a stock buyback?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.